Sutro Biopharma STRO 深 滬
等待開盤 12-11 09:30:00 美东时间
9.00
+0.510
+6.01%
華盛通- 最 高9.17
- 今 開8.38
- 成交量 12.76万股
- 最 低 8.2285
- 昨 收 8.49
- 總市值 7662.15万
- 52周最高 21.50
- 市盈率 靜 --
- 換手率 1.50%
- 52周最低 5.231
- 委 比 -66.31%
- 總股本 851.35万
- 歷史最高 283.00
- 量 比 0.80
- 振 幅 11.09%
- 歷史最低 5.231
- 每 手 1
- 風險率 4.65%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Vaxcyte Doses First Participants in the OPUS Phase 3, Noninferiority Trial Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease and Pneumonia in Adults
Vaxcyte has initiated the Phase 3 OPUS trial for VAX-31, aiming to establish noninferiority and superiority over existing PCVs in adults. Designed to expand coverage against a broader range of pneumococcal serotypes, VAX-31 targets approximately 95% coverage for IPD and 88% for pneumonia in U.S. adults aged 50+. Topline data anticipated in Q4 2026 will support BLA submission.
12-08 12:00
Sutro Biopharma falls as it announces 1-for-10 reverse stock split
Sutro Biopharma (STRO) said on Monday that its board has approved a reverse stock split of the company's outstanding shares of common stock at a ratio of 1-for-10. Sutro’s common stock will begin tr...
12-01 21:16
Sutro Biopharma Announces 1-For-10 Reverse Stock Split, Effective Dec. 3
Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced that its Board of Directors
12-01 21:04
Sutro Biopharma Reports Third Quarter 2025 Financial Results and Business Highlights
Sutro Biopharma announced FDA clearance for its IND application for STRO-004, a potential best-in-class Tissue Factor ADC, and expects to dose the first patient before year-end. The company presented new preclinical data highlighting novel dual-payload ADCs designed to overcome resistance and delay progression. Sutro also reported $167.6 million in cash, cash equivalents, and marketable securities as of September 30, 2025, with a cash runway exte...
11-06 21:30
Sutro Biopharma Announces Participation at the 16th Annual World ADC Conference
Sutro Biopharma announced its participation in the 16th Annual World ADC Conference in San Diego, November 3-6, 2025. The company highlighted new preclinical data showcasing its innovative dual-payload antibody drug conjugates (ADCs), which aim to enhance therapeutic index and address tumor resistance in oncology. Presentations will cover site-specific, high-DAR ADCs, immunostimulatory ADCs, and the development of STRO-006 targeting integrin beta...
11-03 13:00
Two Seas Capital Expresses Enthusiasm for Core Scientific's Future Prospects
Issues Letter to Shareholders Highlighting Significant Upside Potential If Proposed Sale to CoreWeave Is Not Approved Urges Shareholders to Vote AGAINST the Ill-Advised Transaction on the GO...
10-28 20:30
What's Driving Beyond Meat's 11% After-Hours Drop?
Beyond Meat shares fell 11% after hours following a volatile rally sparked by ETF inclusion and short-selling activity.
10-23 13:50
Latest Beyond Meat Short-Seller? Martin Shkreli, Of Course
Martin Shkreli shorts Beyond Meat stock as it ripped higher Wednesday.
10-22 23:20
Beyond Meat shares rally in heavy volume trading
Shares of plant-based meat company Beyond Meat (NASDAQ:BYND) have nearly doubled in value by midday on Monday in heavy volume trading. BYND is up 83.6% at $1.19 by 1:05pm ET. The stock rose as much as...
10-21 01:10
Lifeway and Danone Sign Cooperation Agreement
New Independent Directors to be Added Stockholders' Agreement Litigation is Stayed Lifeway is Evaluating Capital Allocation Alternatives to Maximize Value Danone Will Not Vote or Deliver Co...
10-01 05:10
